RxDoctor Payments Data

Mackenzie Pettinella, PA

Medical · Rochester, NYNPI 1003257809

Payments from drug & device makers

$3,194in general payments, 2019–2025

Across 128 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$518
  • Boston Scientific$436
  • E.r. Squibb & Sons, L.L.C.$367
  • Boehringer Ingelheim$274
  • Kiniksa Pharmaceuticals International, PLC$202
  • Pfizer$186
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,194 in reported general payments places this provider in the 80th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$8,215
Medicare patients
84
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$148,802
XareltoRivaroxaban17$17,378
Dofetilide26$5,321
Metoprolol Succinate115$2,195
Amiodarone Hcl37$1,022
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$726
Nadolol30$718
Pantoprazole Sodium67$401
Flecainide Acetate11$394
Nebivolol Hcl13$381
Cartia XtDiltiazem Hcl11$316
SotalolSotalol Hcl14$313
Metoprolol Tartrate43$246
ClopidogrelClopidogrel Bisulfate32$121
Carvedilol13$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$148,802153 claims
Johnson & JohnsonXarelto$161$17,37817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,395 medical providers in New York.

Other medical in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →